Mitral valve‐in‐valve and valve‐in‐ring procedures: Midterm outcomes in a French nationwide registry

Objectives Report contemporary outcomes in patients included in the Mitragister registry and treated with transcatheter mitral valve implantation for failed surgical annuloplasty rings or deteriorated bioprosthesis. Background Midterm survival rates have been reported, but little is known about cont...

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2022-05, Vol.99 (6), p.1829-1838
Main Authors: Le Ruz, Robin, Guérin, Patrice, Leurent, Guillaume, Leroux, Lionel, Lefevre, Thierry, Nejjari, Mohammed, Champagnac, Didier, Tchétché, Didier, Lhermusier, Thibault, Senage, Thomas, Piriou, Pierre‐Guillaume, Caussin, Christophe, Delomez, Maxence, Bonnet, Guillaume, Favereau, Xavier, Karam, Nicole, Gerbay, Antoine, Juthier, Francis, Gilard, Martine, Obadia, Jean‐Francois, Iung, Bernard, Manigold, Thibaut
Format: Article
Language:English
Subjects:
Aged, 80 and over
Bioprosthesis - adverse effects
Cardiac Catheterization - methods
Cardiovascular diseases
Congestive heart failure
Female
heart failure
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation - methods
Humans
Life Sciences
Male
Medical prognosis
Mitral valve
Mitral Valve - diagnostic imaging
Mitral Valve - surgery
mitral valve disease
Mitral Valve Insufficiency - diagnostic imaging
Mitral Valve Insufficiency - surgery
Multivariate analysis
paravalvular leak
Patients
percutaneous intervention
percutaneous valve therapy
Prosthesis Failure
Registries
Regurgitation
Safety
Stroke Volume
structural heart disease intervention
Treatment Outcome
Ventricle
Ventricular Function, Left
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Report contemporary outcomes in patients included in the Mitragister registry and treated with transcatheter mitral valve implantation for failed surgical annuloplasty rings or deteriorated bioprosthesis. Background Midterm survival rates have been reported, but little is known about contemporary morbimortality endpoints. Methods The primary safety outcome was the technical success rate. The primary efficacy composite endpoint was a composite of cardiovascular mortality and heart failure hospitalizations. Results From 2016 to 2021, 102 patients (median age: 81 [74;84] years, 61% female, Euroscore II 11.0% [7.8;16.0]) undergoing valve‐in‐valve (ViV; n = 89) or valve‐in‐ring (ViR; n = 13) procedures were consecutively included. At baseline, ViR group patients had worse left ventricular ejection fraction (50% vs. 60%; p = 0.004) and more frequently severe regurgitation (46% vs. 15%; p = 0.014). The primary safety outcome was 95%: 77% and 98% in the ViR and ViV populations, respectively, (p = 0.014). At intermediate follow‐up (6–12 months) clinical improvement was notable, 88% of the patients were in NYHA class ≤ II (vs. 25% at baseline; p 
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.30161